Key result
Inhibition of α2δ-1 with gabapentin or genetic knockout prevented FK506-induced increases in synaptic NMDAR activity and the development of hypertension in rodents.
Why the study?
It was unclear how calcineurin inhibitors increase NMDAR activity in the PVN to augment sympathetic vasomotor activity and cause persistent hypertension.
Does inhibition of α2δ-1 with gabapentin or genetic knockout prevent calcineurin inhibitor-induced hypertension in rodent models?
Does inhibition of α2δ-1 with gabapentin or genetic knockout prevent calcineurin inhibitor-induced hypertension in rodent models?
α2δ-1-bound NMDA receptors drive calcineurin inhibitor-induced hypertension, identifying gabapentinoids as a potential repurposed treatment for this condition.
Supports testing gabapentinoids in calcineurin inhibitor hypertension; leaves open efficacy and safety in humans.
BACKGROUND: Calcineurin is highly enriched in immune T cells and the nervous system. Calcineurin inhibitors, including cyclosporine and tacrolimus (FK506), are the cornerstone of immunosuppressive regimens for preserving transplanted organs and tissues. However, these drugs often cause persistent hypertension owing to excess sympathetic outflow, which is maintained by N-methyl-D-aspartate receptor (NMDAR)-mediated excitatory input to the hypothalamic paraventricular nucleus (PVN). It is unclear how calcineurin inhibitors increase NMDAR activity in the PVN to augment sympathetic vasomotor activity. α2δ-1 (encoded by the Cacna2d1 gene), known colloquially as a calcium channel subunit, is a newly discovered NMDAR-interacting protein. In this study, we determined whether α2δ-1 plays a role in calcineurin inhibitor–induced synaptic NMDAR hyperactivity in the PVN and hypertension development. METHODS: Immunoblotting and coimmunoprecipitation assays were used to quantify synaptic protein levels and the physical interaction between GluN1 (the obligatory NMDAR subunit) and α2δ-1. Whole-cell patch-clamp recordings of retrogradely labeled, spinally projecting PVN were conducted in perfused brain slices to measure presynaptic and postsynaptic NMDAR activity. Radio-telemetry was implanted in rodents to continuously record arterial blood pressure in conscious states. RESULTS: Prolonged treatment with FK506 in rats significantly increased protein levels of α2δ-1, GluN1, and the α2δ-1-GluN1 complex in PVN synaptosomes. These effects were blocked by inhibiting α2δ-1 with gabapentin or interrupting the α2δ-1-NMDAR interaction with an α2δ-1 C-terminus peptide. Treatment with FK506 potentiated the activity of presynaptic and postsynaptic NMDARs in spinally projecting PVN neurons; such effects were abolished by gabapentin, Cacna2d1 knockout, or α2δ-1 C-terminus peptide. Furthermore, microinjection of α2δ-1 C-terminus peptide into the PVN diminished renal sympathetic nerve discharges and arterial blood pressure that had been increased by FK506 treatment. Remarkably, concurrent administration of gabapentin prevented the development of FK506-induced hypertension in rats. Additionally, FK506 treatment induced sustained hypertension in wild-type mice but not in Cacna2d1 knockout mice. CONCLUSIONS: α2δ-1 is essential for calcineurin inhibitor–induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor–induced hypertension. Gabapentinoids (gabapentin and pregabalin) could be repurposed for treating calcineurin inhibitor–induced neurogenic hypertension.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) studied Calcineurin inhibitor-induced hypertension. FK506 (tacrolimus) with or without gabapentin / Cacna2d1 knockout vs. Control/Wild-type was evaluated on Synaptic NMDAR activity, sympathetic nerve discharges, and arterial blood pressure. Inhibition of α2δ-1 with gabapentin or genetic knockout prevented FK506-induced increases in synaptic NMDAR activity and the development of hypertension in rodents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: